Moreover, we discussed the efficacy of immunotherapy in driven gene mutations in lung cancer, including KRAS, TP53, EGFR, ALK, ROS1, KEAP1, ZFHX3, PTCH1, and STK11. This evidence concerns the gene TP53 and lung carcinoma.